NCT06111196View on ClinicalTrials.gov

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 5, 2023

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2024

Conditions
Healthy Male Subjects
Interventions
DRUG

Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection

100mg/4ml;single dose;intravenous injection

DRUG

Pembrolizumab injection

100mg/4ml;single dose;intravenous injection

Trial Locations (1)

Unknown

Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY

NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects | Biotech Hunter | Biotech Hunter